Back to results
US 2022/0175975 A1Published application
HER3 Peptides for Imaging and Radiotherapy
AssigneeThe General Hospital Corporation
InventorsUmar Mahmood, Benjamin Larimer
Life of this patent
Estimating the term…
Abstract
Provided herein are compositions useful for imaging HER3. An exemplary composition provided herein is useful as a radiotracer for position emission tomography (PET) imaging. Methods of imaging HER3 and combination therapies comprising the HER3 imaging agents are also provided.
Claims21
1-56. (canceled)
A composition of Formula II:
- B-C,
- wherein:
- B comprises a sequence:
- and
- C comprises a sequence:
- wherein:
- refers to the bond between C and B;
- refers to a disulfide bond between the cysteine groups;
- refers to the bond between B and C;
- X2 is selected from the group consisting of L, L*, I, I*, P, P*, V, V*, G, and G*;
- X3 is selected from the group consisting of P, P*, L, L*, I, I*, V, V*, G, and G*;
- X4 is selected from the group consisting of T, T*, S, S*, C, C*, M, and M*;
- X5 is selected from the group consisting of any L-amino acid, any D-amino acid, and any non-natural amino acid;
- X6 is selected from the group consisting of any L-amino acid, any D-amino acid, and any non-natural amino acid;
- X7 is selected from the group consisting of R, R*, H, H*, K, K*, N, N*, Q, and Q*, and
- X8 is selected from the group consisting of S, S*, T, T*, C, C*, M, and M*,
- X9 is selected from the group consisting of beta A, 6-aminohexanoic acid, 8-aminooctanoic acid, and 2-(2-(2-aminoethoxy)ethoxy)acetic acid;
- X10 is selected from the group consisting of G, G*, A, A*, S, S*, P, P*, W, W*, Y, Y*, H, H*, T, T*, M, M*, N, N*, Q, and Q*;
- X11 is selected from the group consisting of G, G*, A, A*, S, S*, P, P*, W, W*, Y, Y*, H, H*, T, T*, M, M*, N, N*, Q, and Q*;
- X12 is selected from the group consisting of G, G*, A, A*, S, S*, P, P*, W, W*, Y, Y*, H, H*, T, T*, M, M*, N, N*, Q, and Q*;
- wherein:
- L* is a non-natural derivative of L;
- I* is a non-natural derivative of I;
- P* is a non-natural derivative of P;
- V* is a non-natural derivative of V;
- G* is a non-natural derivative of G;
- T* is a non-natural derivative of T;
- S* is a non-natural derivative of S;
- C* is a non-natural derivative of C;
- M* is a non-natural derivative of M;
- R* is a non-natural derivative of R;
- H* is a non-natural derivative of H;
- K* is a non-natural derivative of K;
- N* is a non-natural derivative of N;
- Q* is a non-natural derivative of Q;
- A* is a non-natural derivative of A;
- W* is a non-natural derivative of W;
- and
- Y* is a non-natural derivative of Y.
36 more elements
A method of imaging cancer in a subject, the method comprising:
- i) administering to the subject an effective amount of a composition of Formula Ia, Formula Ib, or Formula Ic:
- wherein A is an imaging agent;
- wherein A′ is a radioisotope;
- wherein
- refers to a disulfide bond between the cysteine groups;
- X2 is selected from the group consisting of L, L*, I, I*, P, P*, V, V*, G, and G*;
- X3 is selected from the group consisting of P, L*, L, L*, I, I*, V, G, and G*;
- X4 is selected from the group consisting of T, T*, S, S*, C, C*, M, and M*;
- X5 is selected from the group consisting of any L-amino acid, any D-amino acid, and any non-natural amino acid;
- X6 is selected from the group consisting of any L-amino acid, any D-amino acid, and any non-natural amino acid;
- X7 is selected from the group consisting of R, R*, H, H*, K, K*, N, N*, Q, and Q*, and
- X8 is selected from the group consisting of S, S*, T, T*, C, C*, M, and M*, wherein:
- L* is a non-natural derivative of L;
- I* is a non-natural derivative of I;
- P* is a non-natural derivative of P;
- V* is a non-natural derivative of V;
- G* is a non-natural derivative of G;
- T* is a non-natural derivative of T;
- S* is a non-natural derivative of S;
- C* is a non-natural derivative of C;
- M* is a non-natural derivative of M;
- R* is a non-natural derivative of R;
- H* is a non-natural derivative of H;
- K* is a non-natural derivative of K;
- N* is a non-natural derivative of N;
- and
- Q* is a non-natural derivative of Q;
- and
- ii) imaging the subject with a suitable imaging technique.
26 more elements
A method of treating a cancer in a subject, the method comprising:
- i) administering to the subject an effective amount of a composition of Formula Ia, Formula Ib, or Formula Ic:
- wherein A is an imaging agent;
- wherein A′ is a radioisotope;
- wherein
- refers to a disulfide bond between the cysteine groups;
- X2 is selected from the group consisting of L, L*, I, I*, P, P*, V, V*, G, and G*;
- X3 is selected from the group consisting of P, P*, L, L*, I, I*, V, V*, G, and G*;
- X4 is selected from the group consisting of T, T*, S, S*, C, C*, M, and M*;
- X5 is selected from the group consisting of any L-amino acid, any D-amino acid, and any non-natural amino acid;
- X6 is selected from the group consisting of any L-amino acid, any D-amino acid, and any non-natural amino acid;
- X7 is selected from the group consisting of R, R*, H, H*, K, K*, N, N*, Q, and Q*, and
- X8 is selected from the group consisting of S, S*, T, T*, C, C*, M, and M*,
- wherein:
- L* is a non-natural derivative of L;
- I* is a non-natural derivative of I;
- P* is a non-natural derivative of P;
- V* is a non-natural derivative of V;
- G* is a non-natural derivative of G;
- T* is a non-natural derivative of T;
- S* is a non-natural derivative of S;
- C* is a non-natural derivative of C;
- M* is a non-natural derivative of M;
- R* is a non-natural derivative of R;
- H* is a non-natural derivative of H;
- K* is a non-natural derivative of K;
- N* is a non-natural derivative of N;
- and
- Q* is a non-natural derivative of Q;
- ii) imaging the subject with a suitable imaging technique;
- and
- iii) administering to the subject a therapeutically effective amount of one or more therapeutic agents.
28 more elements
Dependencies are inferred from the claim text.